u/forest_plot_fiona

Came off sema and onto tirz with a two-week gap. The first month was flat and I assumed I had made a mistake. Month two it moved.

Which trial and which readout?

Retitled: the original quoted a diabetes endpoint as an obesity result.

Added ApoB to the panel after a thread here. It told me something the standard lipid panel had been hiding.

It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads. That is why the side-effect profile reads differently rather than just milder.

My ALT moved and I spent a fortnight convinced I knew why. The repeat six weeks later was back in range and I had changed nothing.

Agreed on assay changes. A lab switching platforms between your draws is invisible unless you ask.

Went 10 to 12.5 on the calendar and had the worst fortnight of the whole run. Dropped back to 10 and everything settled.

It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads. That is why the side-effect profile reads differently rather than just milder.

Disagree — you are quoting a combination arm as though it were monotherapy. Those are different results.

Fertility changed faster than I expected with the weight loss. Nobody had raised it and I wish somebody had.

Why so many single values look alarming and turn out to be nothing.

A reference interval is built to contain about 95% of a healthy reference population, so one test in twenty falls outside one by construction. Add biological variation, assay imprecision, fasting state and time of day, and a genuinely stable person will produce occasional out-of-range results.

That is why repeat testing before acting is standard. Regression to the mean handles most of it. None of which means an out-of-range value should be ignored — it means it should be repeated and taken to somebody who can put it in context, which is emphatically not a ranked feed.

2.5mg is a four-week starting dose, not a maintenance dose. Worth being precise since people search these threads.

Not convinced by the attribution. Weight loss alone moves that marker and you have no way to separate the two.

The four-week interval in the label is a minimum. Nothing about the pharmacology requires you to step on schedule, and the trials stepped on a calendar because trials have to.

The step schedule question, answered properly, because it comes up weekly.

The label sets a minimum interval of four weeks between increases. That is a floor on how fast you may go, and it exists because tolerability, not efficacy, is what limits most people. There is nothing in the pharmacology that says you must increase at four weeks, or at eight, or ever.

What decides it in practice is whether the effect you want is still there. If appetite is quiet and the trend is going the right way, the dose is doing its job. If both have genuinely gone flat for six weeks or more, that is a conversation worth having with someone who knows your history.

Same experience with the appetite effect being flatter across the week rather than front-loaded.

Time of day, fasting state, hydration and recent exercise all move common markers. Standardising the draw conditions is free and it removes most of the apparent variability.

Appetite effect for me is flat across seven days. On sema it was a wave. Same person, different molecule.

the monotherapy numbers are modest and that is not the point

The honest state of the evidence on this board, since somebody should write it down.

Published clinical data exists and is genuinely interesting, particularly in combination. Independent purity data from members is thin — a handful of results across the whole site, against hundreds for the older molecules. Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.

What follows practically: buy small if you buy at all, test what you get and post the result, and treat confident rankings against established compounds as the extrapolation they are. The board gets better as the log fills, and right now the log is nearly empty.

iron and ferritin questions come up here more than anywhere else on the site

Correction: that marker is reported in different units by different labs, which explains the tenfold difference you are seeing.

Left up and flaired Trial Data. The publication is linked rather than the coverage, which is what we ask for.

the confidence interval is the finding, the point estimate is the headline

Small fix — that was the cardiovascular outcomes trial, so weight was a secondary endpoint and the population was different.

Small fix — a reference interval is not a treatment target, and the post above uses them interchangeably.

Right — trial participants get structured support. Comparing yourself to a trial mean is comparing across two different interventions.

Left up and flaired Trial Data. The publication is linked rather than the coverage, which is what we ask for.

Agreed on assay changes. A lab switching platforms between your draws is invisible unless you ask.

Disagree with reading anything into that.

Disagreeing with this bit: that change is confounded by the weight loss itself and cannot be attributed.

This matches mine. Milder muscle cramps than I expected, and what there was settled inside a fortnight of each step.

the trials titrated on a calendar, real people titrate on symptoms

That is a non-fasting value and the interval you are comparing it against is a fasting one.

Agreed — and standardising the draw conditions is the cheapest improvement available.

What did the repeat show?

29kg over 94 weeks, never went past 10mg, and food noise stayed mild the whole way. Posting because the loud threads are all 15mg.

Small fix: SURMOUNT is the obesity programme, SURPASS is the type-2 programme. They are different endpoints and the numbers do not transfer.

Brought the whole set to my clinician rather than one flagged value. Completely different conversation.

Correction: SURMOUNT is the obesity programme and SURPASS is the diabetes one. The figure you quoted belongs to the other one.

hold the dose that works, the ladder is not a leaderboard